Market closed

Summit Therapeutics/$SMMT

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Summit Therapeutics

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Ticker

$SMMT
Trading on

Industry

Biotechnology

Employees

105

SMMT Metrics

BasicAdvanced
$14B
Market cap
-
P/E ratio
-$0.28
EPS
-0.92
Beta
-
Dividend rate
$14B
-0.92
$28.73
$2.10
1.9M
8.309
8.262
0.961
7.421
-15.69%
-31.45%
-73.20%
30.97
31.11
-101.97
-74.54%
-31.35%

What the Analysts think about SMMT

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Summit Therapeutics stock.

SMMT Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

SMMT Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SMMT

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Summit Therapeutics stock?

Summit Therapeutics (SMMT) has a market cap of $14B as of December 21, 2024.

What is the P/E ratio for Summit Therapeutics stock?

The price to earnings (P/E) ratio for Summit Therapeutics (SMMT) stock is 0 as of December 21, 2024.

Does Summit Therapeutics stock pay dividends?

No, Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders as of December 21, 2024.

When is the next Summit Therapeutics dividend payment date?

Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders.

What is the beta indicator for Summit Therapeutics?

Summit Therapeutics (SMMT) has a beta rating of -0.92. This means that it has an inverse relation to market volatility.